SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
BURLINGTON, Mass., April 30, 2018 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2018 financial results after the close of the U.S. financial markets on Tuesday, May 8, 2018. Flexion’s management will host a conference call at 4:30 p.m. ET to discuss the results and provide an update on business operations.
The dial-in number for the conference call is 1-855-770-0022 for domestic participants and 1-908-982-4677 for international participants, with Conference ID #2880817. A live webcast of the conference call can also be accessed through the "Investors" tab on the Flexion Therapeutics website. A webcast replay will be available online after the call.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. For the past two years, Flexion has been named one of the Best Places to Work by the Boston Business Journal, and Flexion was also recognized as a Top Place to Work in Massachusetts by The Boston Globe in 2017.
Contact:
Scott Young
Vice President, Corporate Communications and Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
[email protected]
